TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
AstraZeneca AB
Closing information (x1000 NOK)
Closing information | 2023/12 | 2022/12 | 2021/12 |
Turnover |
183,839,932
|
156,304,502
|
111,236,771 |
Financial expenses |
550,076
|
1,440,625
|
454,454 |
Earnings before taxes |
83,833,440
|
-19,544,448
|
22,450,590 |
EBITDA |
42,264,697
|
27,952,665
|
25,079,790 |
Total assets |
370,015,915
|
255,456,014
|
308,233,607 |
Current assets |
37,700,989
|
31,933,066
|
31,163,226 |
Current liabilities |
24,589,319
|
23,601,467
|
19,757,027 |
Equity capital |
314,597,711
|
200,068,287
|
255,061,274 |
- share capital |
2,080,767
|
1,942,905
|
2,003,106 |
Employees (average) |
7,248
|
6,875
|
6,814 |
Financial ratios
Fiscal year | 2023/12 | 2022/12 | 2021/12 |
Solvency |
85.0%
|
78.3%
|
82.7% |
Turnover per employee |
25,364
|
22,735
|
16,325 |
Profit as a percentage of turnover |
45.6%
|
-12.5%
|
20.2% |
Return on assets (ROA) |
22.8%
|
-7.1%
|
7.4% |
Current ratio |
153.3%
|
135.3%
|
157.7% |
Return on equity (ROE) |
26.6%
|
-9.8%
|
8.8% |
Change turnover |
16,444,544
|
48,410,865
|
6,614,932 |
Change turnover % |
10%
|
45%
|
6% |
Chg. No. of employees |
373
|
61
|
181 |
Chg. No. of employees % |
5%
|
1%
|
3% |
Total value of public sale
Fiscal year | 2023/12 | 2022/12 | 2021/12 |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.